Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003464855 | SCV004206449 | pathogenic | Retinitis pigmentosa 39 | 2021-12-20 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004587499 | SCV005075899 | likely pathogenic | Usher syndrome | 2024-04-02 | criteria provided, single submitter | clinical testing | Variant summary: USH2A c.7594+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a canonical 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4e-06 in 250816 control chromosomes (gnomAD). c.7594+1G>A has been reported in the literature in at-least one individual affected with inherited retinal disease (IRD) (example: Gao_2021). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 32188678, 36110214, 29625443). ClinVar contains an entry for this variant (Variation ID: 2679574). Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Fulgent Genetics, |
RCV005012979 | SCV005638780 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2024-04-04 | criteria provided, single submitter | clinical testing |